Jemperli’s was approved for the first-line ... a quick chat with the Grove.AI team about their new AI agent for clinical trial recruitment. AstraZeneca has become the first company to get ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

AnaptysBio discovered Jemperli, which was licensed to TESARO ... dedicated to conducting cooperative clinical trials. GSK Oncology, R&D global head and senior vice-president Hesham Abdullah ...

Jemperli has so far failed to make much headway ... a quick chat with the Grove.AI team about their new AI agent for clinical trial recruitment. AstraZeneca has become the first company to get ...

The EC’s latest decision on the drug follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from part one of the late-stage ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for ... and where preliminary clinical evidence may indicate ...

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days ...

GSK’sGSK1.44%increase; green up pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the ...

Jemperli is a programmed death receptor-1 ... the standard of care in gynecologic oncology through cooperative clinical trials. GSK is a global biopharma company focused on uniting science ...

The approval broadens the previous indication for Jemperli plus chemotherapy in ... The company says RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and ...